Provectus Pharmaceuticals, a development-stage oncology and dermatology biopharmaceutical company, has named Stuart Fuchs to its corporate advisory board. He is resigning from the board of directors.
Fuchs was previously a co-founder and managing principal of Gryffindor Capital Partners and before that was with Goldman Sachs for 19 years. Before becoming an investment banker, he practiced law. He also serves as chairman and CEO of CognoSPECTi, a start-up venture.
Dr. Craig Dees, PhD., CEO of Provectus said, “Stuart has provided many years of service to Provectus Pharmaceuticals as a member of our board of directors. As we transition our board of directors to becoming an independent board, Stuart, who has been a consultant to Provectus Pharmaceuticals, has agreed to transition off our board of directors, and join our corporate advisory board, where he will still remain active as an advisor to our company.”